FGF19 and primary biliary cholangitis: The FGF-19 analog aldafermin (NGM 282) has been shown to improve liver fibrosis, which theoretically may reduce the incidence of cirrhosis within this patient population.28 In PBC patients who had failed UDCA, NGM 282 over 28 days resulted in reduction of ALP and transaminase levels compared with placebo, with an acceptable safety profile.29